SREBF1 and fatty liver disease: Moreover, O‐GlcNAcylation of SREBP‐1 plays a crucial role in changing hepatic lipid synthesis and the progression of fatty liver disease.[30] Inhibition of O‐GlcNAcylation of nuclear factor‐κB (NF‐κB) has been found to reduce hepatic steatosis.[31] Our research aligns with these findings, demonstrating that inhibiting O‐GlcNAcylation with BAGN effectively inhibits lipid accumulation, inflammation, and collagen deposition, and promotes liver function recovery in HFD‐fed and CDAHFD‐fed mice.